LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.

    Khurshed, Mohammed / Molenaar, Remco J / Lenting, Krissie / Leenders, William P / van Noorden, Cornelis J F

    Oncotarget

    2017  Volume 8, Issue 30, Page(s) 49165–49177

    Abstract: Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) initiate low-grade glioma and secondary glioblastoma and induce a neomorphic activity that converts α-ketoglutarate (α-KG) to the oncometabolite D-2-hydroxyglutarate (D-2-HG). It causes metabolic ... ...

    Abstract Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) initiate low-grade glioma and secondary glioblastoma and induce a neomorphic activity that converts α-ketoglutarate (α-KG) to the oncometabolite D-2-hydroxyglutarate (D-2-HG). It causes metabolic rewiring that is not fully understood. We investigated the effects of IDH1 mutations (IDH1MUT) on expression of genes that encode for metabolic enzymes by data mining The Cancer Genome Atlas. We analyzed 112 IDH1 wild-type (IDH1WT) versus 399 IDH1MUT low-grade glioma and 157 IDH1WT versus 9 IDH1MUT glioblastoma samples. In both glioma types, IDH1WT was associated with high expression levels of genes encoding enzymes that are involved in glycolysis and acetate anaplerosis, whereas IDH1MUT glioma overexpress genes encoding enzymes that are involved in the oxidative tricarboxylic acid (TCA) cycle. In vitro, we observed that IDH1MUT cancer cells have a higher basal respiration compared to IDH1WT cancer cells and inhibition of the IDH1MUT shifts the metabolism by decreasing oxygen consumption and increasing glycolysis. Our findings indicate that IDH1WT glioma have a typical Warburg phenotype whereas in IDH1MUT glioma the TCA cycle, rather than glycolytic lactate production, is the predominant metabolic pathway. Our data further suggest that the TCA in IDH1MUT glioma is driven by lactate and glutamate anaplerosis to facilitate production of α-KG, and ultimately D-2-HG. This metabolic rewiring may be a basis for novel therapies for IDH1MUT and IDH1WT glioma.
    Language English
    Publishing date 2017-07-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.17106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Imaging Hyperpolarized Pyruvate and Lactate after Blood-Brain Barrier Disruption with Focused Ultrasound.

    Peeters, Tom H / Kobus, Thiele / Breukels, Vincent / Lenting, Krissie / Veltien, Andor / Heerschap, Arend / Scheenen, Tom W J

    ACS chemical neuroscience

    2019  Volume 10, Issue 5, Page(s) 2591–2601

    Abstract: Imaging of ... ...

    Abstract Imaging of hyperpolarized
    MeSH term(s) Animals ; Blood-Brain Barrier/physiology ; Carbon-13 Magnetic Resonance Spectroscopy/methods ; Lactic Acid/metabolism ; Magnetic Resonance Imaging, Interventional/methods ; Metabolic Networks and Pathways/physiology ; Mice ; Microscopy, Polarization/methods ; Pyruvic Acid/metabolism ; Ultrasonic Waves
    Chemical Substances Lactic Acid (33X04XA5AT) ; Pyruvic Acid (8558G7RUTR)
    Language English
    Publishing date 2019-03-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1948-7193
    ISSN (online) 1948-7193
    DOI 10.1021/acschemneuro.9b00085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Glioma: experimental models and reality.

    Lenting, Krissie / Verhaak, Roel / Ter Laan, Mark / Wesseling, Pieter / Leenders, William

    Acta neuropathologica

    2017  Volume 133, Issue 2, Page(s) 263–282

    Abstract: In theory, in vitro and in vivo models for human gliomas have great potential to not only enhance our understanding of glioma biology, but also to facilitate the development of novel treatment strategies for these tumors. For reliable prediction and ... ...

    Abstract In theory, in vitro and in vivo models for human gliomas have great potential to not only enhance our understanding of glioma biology, but also to facilitate the development of novel treatment strategies for these tumors. For reliable prediction and validation of the effects of different therapeutic modalities, however, glioma models need to comply with specific and more strict demands than other models of cancer, and these demands are directly related to the combination of genetic aberrations and the specific brain micro-environment gliomas grow in. This review starts with a brief introduction on the pathological and molecular characteristics of gliomas, followed by an overview of the models that have been used in the last decades in glioma research. Next, we will discuss how these models may play a role in better understanding glioma development and especially in how they can aid in the design and optimization of novel therapies. The strengths and weaknesses of the different models will be discussed in light of genotypic, phenotypic and metabolic characteristics of human gliomas. The last part of this review provides some examples of how therapy experiments using glioma models can lead to deceptive results when such characteristics are not properly taken into account.
    MeSH term(s) Animals ; Brain Neoplasms ; Glioma ; Humans ; Models, Theoretical
    Language English
    Publishing date 2017-01-10
    Publishing country Germany
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1079-0
    ISSN 1432-0533 ; 0001-6322
    ISSN (online) 1432-0533
    ISSN 0001-6322
    DOI 10.1007/s00401-017-1671-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Isocitrate dehydrogenase 1

    Peeters, Tom H / Lenting, Krissie / Breukels, Vincent / van Lith, Sanne A M / van den Heuvel, Corina N A M / Molenaar, Remco / van Rooij, Arno / Wevers, Ron / Span, Paul N / Heerschap, Arend / Leenders, William P J

    Cancer & metabolism

    2019  Volume 7, Page(s) 4

    Abstract: Background: Mutations in isocitrate dehydrogenase 1 (: Methods: We performed : Results: Significant amounts of : Conclusions: This work shows that glutamate can be directly processed ... ...

    Abstract Background: Mutations in isocitrate dehydrogenase 1 (
    Methods: We performed
    Results: Significant amounts of
    Conclusions: This work shows that glutamate can be directly processed into
    Language English
    Publishing date 2019-05-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2700141-6
    ISSN 2049-3002
    ISSN 2049-3002
    DOI 10.1186/s40170-019-0198-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing.

    Lenting, Krissie / van den Heuvel, Corina N A M / van Ewijk, Anne / ElMelik, Duaa / de Boer, Remco / Tindall, Elizabeth / Wei, Ge / Kusters, Benno / Te Dorsthorst, Maarten / Ter Laan, Mark / Huynen, Martijn A / Leenders, William P

    Acta neuropathologica communications

    2019  Volume 7, Issue 1, Page(s) 185

    Abstract: Many biology-based precision drugs are available that neutralize aberrant molecular pathways in cancer. Molecular heterogeneity and the lack of reliable companion diagnostic biomarkers for many drugs makes targeted treatment of cancer inaccurate for many ...

    Abstract Many biology-based precision drugs are available that neutralize aberrant molecular pathways in cancer. Molecular heterogeneity and the lack of reliable companion diagnostic biomarkers for many drugs makes targeted treatment of cancer inaccurate for many individuals. Identifying actionable hyperactive biological pathways in individual cancers may improve this situation.To achieve this we applied a novel targeted RNA next generation sequencing (t/RNA-NGS) technique to surgically obtained glioma tissues. The test combines mutation detection with analysis of biological pathway activities that are involved in tumour behavior in many cancer types (e.g. tyrosine kinase signaling, angiogenesis signaling, immune response, metabolism), via quantitative measurement of transcript levels and splice variants of hundreds of genes. We here present proof of concept that the technique, which uses molecular inversion probes, generates a histology-independent molecular diagnosis and identifies classifiers that are strongly associated with conventional histopathology diagnoses and even with patient prognosis. The test not only confirmed known glioma-associated molecular aberrations but also identified aberrant expression levels of actionable genes and mutations that have so far been considered not to be associated with glioma, opening up the possibility of drug repurposing for individual patients. Its cost-effectiveness makes t/RNA-NGS to an attractive instrument to aid oncologists in therapy decision making.
    MeSH term(s) Adult ; Aged ; Biomarkers, Tumor/genetics ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Chromosome Mapping/methods ; Female ; Gene Targeting/methods ; Glioma/genetics ; Glioma/pathology ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Sequence Analysis, RNA/methods ; Young Adult
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2019-11-20
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2715589-4
    ISSN 2051-5960 ; 2051-5960
    ISSN (online) 2051-5960
    ISSN 2051-5960
    DOI 10.1186/s40478-019-0826-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.

    Lenting, Krissie / Khurshed, Mohammed / Peeters, Tom H / van den Heuvel, Corina N A M / van Lith, Sanne A M / de Bitter, Tessa / Hendriks, Wiljan / Span, Paul N / Molenaar, Remco J / Botman, Dennis / Verrijp, Kiek / Heerschap, Arend / Ter Laan, Mark / Kusters, Benno / van Ewijk, Anne / Huynen, Martijn A / van Noorden, Cornelis J F / Leenders, William P J

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

    2018  Volume 33, Issue 1, Page(s) 557–571

    Abstract: Diffuse gliomas often carry point mutations in isocitrate dehydrogenase ( ... ...

    Abstract Diffuse gliomas often carry point mutations in isocitrate dehydrogenase ( IDH1
    MeSH term(s) 4-Aminobutyrate Transaminase/genetics ; 4-Aminobutyrate Transaminase/metabolism ; Animals ; Brain Neoplasms/genetics ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Glioma/genetics ; Glioma/metabolism ; Glioma/pathology ; Glutamate Dehydrogenase/genetics ; Glutamate Dehydrogenase/metabolism ; Glutamic Acid/metabolism ; Glutaminase/genetics ; Glutaminase/metabolism ; Humans ; Isocitrate Dehydrogenase/genetics ; Isocitrate Dehydrogenase/metabolism ; Lactic Acid/metabolism ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mutation ; Neoplasm Invasiveness ; Stress, Physiological ; Succinate-Semialdehyde Dehydrogenase/genetics ; Succinate-Semialdehyde Dehydrogenase/metabolism ; Transcriptome ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
    Chemical Substances Lactic Acid (33X04XA5AT) ; Glutamic Acid (3KX376GY7L) ; Isocitrate Dehydrogenase (EC 1.1.1.41) ; IDH1 protein, human (EC 1.1.1.42.) ; ALDH5A1 protein, human (EC 1.2.1.24) ; Succinate-Semialdehyde Dehydrogenase (EC 1.2.1.24) ; Glutamate Dehydrogenase (EC 1.4.1.2) ; GLUD1 protein, human (EC 1.4.1.3) ; 4-Aminobutyrate Transaminase (EC 2.6.1.19) ; GLS protein, human (EC 3.5.1.2) ; Glutaminase (EC 3.5.1.2)
    Language English
    Publishing date 2018-07-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639186-2
    ISSN 1530-6860 ; 0892-6638
    ISSN (online) 1530-6860
    ISSN 0892-6638
    DOI 10.1096/fj.201800907RR
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.

    van Lith, Sanne A M / Navis, Anna C / Lenting, Krissie / Verrijp, Kiek / Schepens, Jan T G / Hendriks, Wiljan J A J / Schubert, Nil A / Venselaar, Hanka / Wevers, Ron A / van Rooij, Arno / Wesseling, Pieter / Molenaar, Remco J / van Noorden, Cornelis J F / Pusch, Stefan / Tops, Bastiaan / Leenders, William P J

    Scientific reports

    2016  Volume 6, Page(s) 30486

    Abstract: The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. These mutations mostly involve Arg132 in IDH1, and Arg172 or Arg140 in IDH2. ...

    Abstract The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. These mutations mostly involve Arg132 in IDH1, and Arg172 or Arg140 in IDH2. Whereas IDHs convert isocitrate to alpha-ketoglutarate (α-KG) with simultaneous reduction of NADP(+) to NADPH, these IDH mutants reduce α-KG to D-2-hydroxyglutarate (D-2-HG) while oxidizing NADPH. D-2-HG is a proposed oncometabolite, acting via competitive inhibition of α-KG-dependent enzymes that are involved in metabolism and epigenetic regulation. However, much less is known about the implications of the metabolic stress, imposed by decreased α-KG and NADPH production, for tumor biology. We here present a novel heterozygous IDH1 mutation, IDH1(R314C), which was identified by targeted next generation sequencing of a high grade glioma from which a mouse xenograft model and a cell line were generated. IDH1(R314C) lacks isocitrate-to-α-KG conversion activity due to reduced affinity for NADP(+), and differs from the IDH1(R132) mutants in that it does not produce D-2-HG. Because IDH1(R314C) is defective in producing α-KG and NADPH, without concomitant production of the D-2-HG, it represents a valuable tool to study the effects of IDH1-dysfunction on cellular metabolism in the absence of this oncometabolite.
    MeSH term(s) Animals ; Astrocytoma/enzymology ; Astrocytoma/genetics ; Base Sequence ; Binding Sites ; Brain Neoplasms/enzymology ; Brain Neoplasms/genetics ; Cell Line, Tumor ; Glutarates/metabolism ; HEK293 Cells ; Heterozygote ; Humans ; Isocitrate Dehydrogenase/genetics ; Isocitrates/metabolism ; Mice ; Mutation/genetics ; NADP/metabolism ; Neoplasm Grading ; Protein Multimerization
    Chemical Substances Glutarates ; Isocitrates ; alpha-hydroxyglutarate (2889-31-8) ; NADP (53-59-8) ; isocitric acid (9RW6G5D4MQ) ; Isocitrate Dehydrogenase (EC 1.1.1.41) ; IDH1 protein, human (EC 1.1.1.42.)
    Language English
    Publishing date 2016-07-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/srep30486
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.

    Molenaar, Remco J / Botman, Dennis / Smits, Myrthe A / Hira, Vashendriya V / van Lith, Sanne A / Stap, Jan / Henneman, Peter / Khurshed, Mohammed / Lenting, Krissie / Mul, Adri N / Dimitrakopoulou, Dionysia / van Drunen, Cornelis M / Hoebe, Ron A / Radivoyevitch, Tomas / Wilmink, Johanna W / Maciejewski, Jaroslaw P / Vandertop, W Peter / Leenders, William P / Bleeker, Fonnet E /
    van Noorden, Cornelis J

    Cancer research

    2015  Volume 75, Issue 22, Page(s) 4790–4802

    Abstract: Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1(R132H), a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small- ... ...

    Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1(R132H), a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1(R132H) that are being developed for cancer therapy may pose risks with coadministration of radiotherapy. Cancer cells heterozygous for the IDH1(R132H) mutation exhibited less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there were higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects were reversed by the IDH1(R132H) inhibitor AGI-5198. Exposure of IDH1 wild-type cells to D-2-hydroxyglutarate was sufficient to reduce IDH-mediated NADPH production and increase IR sensitivity. Mechanistic investigations revealed that the radiosensitivity of heterozygous cells was independent of the well-described DNA hypermethylation phenotype in IDH1-mutated cancers. Thus, our results argue that altered oxidative stress responses are a plausible mechanism to understand the radiosensitivity of IDH1-mutated cancer cells. Further, they offer an explanation for the relatively longer survival of patients with IDH1-mutated tumors, and they imply that administration of IDH1(R132H) inhibitors in these patients may limit irradiation efficacy in this setting.
    MeSH term(s) Antineoplastic Agents/pharmacology ; Benzeneacetamides/pharmacology ; Blotting, Western ; Cell Line, Tumor ; Chemoradiotherapy/adverse effects ; DNA Methylation/drug effects ; DNA Methylation/radiation effects ; Enzyme Inhibitors/pharmacology ; Fluorescent Antibody Technique ; Gene Knock-In Techniques ; Glioblastoma/genetics ; Glioblastoma/pathology ; Humans ; Imidazoles/pharmacology ; In Vitro Techniques ; Isocitrate Dehydrogenase/genetics ; Mutation ; NADP/biosynthesis ; Oxidative Stress/drug effects ; Oxidative Stress/radiation effects ; Radiation Tolerance/drug effects
    Chemical Substances AGI-5198 ; Antineoplastic Agents ; Benzeneacetamides ; Enzyme Inhibitors ; Imidazoles ; NADP (53-59-8) ; Isocitrate Dehydrogenase (EC 1.1.1.41) ; IDH1 protein, human (EC 1.1.1.42.)
    Language English
    Publishing date 2015-11-15
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-14-3603
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top